Clinical Evidence
Discover results from POLARx™ clinical trials that highlight the benefits of a new cryoablation system
For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
Discover results from POLARx™ clinical trials that highlight the benefits of a new cryoablation system
FROzen AF is a global, prospective, single-arm study, researchers evaluated the safety and effectiveness of the POLARx™ Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation (PAF). 385 patients were enrolled across 44 sites; 50 patients in the POLARx FIT arm.
Procedural Characteristic |
FROzEN-AF (28 mm balloon) |
POLARxᵀᴹ FIT Extension Arm (28 mm / 31 mm balloon) |
General Anesthesia (%) | 78.5% | 100% |
Conscious Sedation/MAC (%) | 21.5% | - |
Procedure Time (min) | 91 ± 41 min |
101 ± 59 min |
LA Dwell Time (min) | 59 ± 33 min | 51 ± 22 min |
Fluoroscopy Time (min) | 12.9 ± 11.2 min | 7.2 ± 11.3 min |
Grade 3-4 Occlusion* (%) | 95.9% (69.9% - Grade 4) | 97.8% (67.3% / 80.8% - Grade 4) |
Single Shot Success* (%) | 55.9% | 35.3% / 62.1% |
*Only ablations with duration >60S included in ablation counts
The choice of balloon sizes (31 and 28 mm) with POLARx FIT may assist in overcoming challenges related to variability in patient PV size and geometry with the 31 mm balloon size.
FROZEN AF (POLARx)
*Safety: Including esophageal fistulas, persistent phrenic nerve palsy and PV stenosis
** 28mm/31mm
Extended POLARx FIT arm
POLAR-ICE is a prospective, non-randomized, single-arm post-market study with 19 participating centers from 7 countries that enrolled 399 patients.
Acute procedural characteristics, efficacy, and safety of a novel cryoballoon for the treatment of paroxysmal atrial fibrillation: Results from the POLAR-ICE study, Tilz et al.
Long-term outcomes for 399 patients with paroxysmal atrial fibrillation treated through PVI with POLARx Cryoablation Catheter demonstrated high effectiveness and safety.
Lower nadir temperatures and a longer thawing time were predictors of clinical success.
A Luik, oral presentation, ESC 2023 Amsterdam
References
1. Anic et al. EP Europace, 2021.
2. Yap, S-C, Anic, A, Breskovic, T, et al. Comparison of procedural efficacy and biophysical parameters between two competing cryoballoon technologies for pulmonary vein isolation: Insights from an initial multicenter experience. J Cardiovasc Electrophysiol. 2021; 32: 580– 587.
3. Kochi, AN, Moltrasio, M, Tundo, F, et al. Cryoballoon atrial fibrillation ablation: Single-center safety and efficacy data using a novel cryoballoon technology compared to a historical balloon platform. J Cardiovasc Electrophysiol. 2021; 32: 588– 594.
4. Creta, A, Kanthasamy, V, Schilling, RJ, et al. First experience of POLARx™ versus Arctic Front Advance™: An early technology comparison. J Cardiovasc Electrophysiol. 2021; 32: 925- 930.
5. Roland Richard Tilz, Roza Meyer-Saraei, Charlotte Eitel, Thomas Fink, Vanessa Sciacca, Lisbeth Delgado Lopez, Bettina Kirstein, Michael Schlüter, Julia Vogler, Karl-Heinz Kuck, Christian-H. Heeger, Novel Cryoballoon Ablation System for Single Shot Pulmonary Vein Isolation ― The Prospective ICE-AGE-X Study ―, Circulation Journal, Article ID CJ-21-0094, Advance online publication April 13, 2021, Online ISSN 1347-4820, Print ISSN 1346-9843, https://doi.org/10.1253/circj.CJ-21-0094, https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-21-0094/_article/-char/en
6. De Asmundis et At. JAfib Jun-Jul 2021, Vol-14 Issue-1.
7. Guckel, D., Lucas, P., Isgandarova, K. et al. Impact of pulmonary vein variant anatomy and cross-sectional orifice area on freedom from atrial fibrillation recurrence after cryothermal single-shot guided pulmonary vein isolation. J Interv Card Electrophysiol (2022). https://doi.org/10.1007/s10840-022-01279-w
8. Guram Imnadze, Thomas Fink, Mustapha El Hamriti, Leonard Bergau, Martin Braun, Moneeb Khalaph, Vanessa Sciacca, Khuraman Isgandarova, Denise Guckel, Christian Sohns, Philipp Sommer. Two competing cryoballoon technologies for single shot pulmonary vein isolation: first experiences with the novel system. Rev. Cardiovasc. Med. 2022, 23(4), 118.
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.